SLC5A1 and breast carcinoma: Our results propose that SGLT1 not only facilities a highly glycolytic phenotype, which supports the tamoxifen resistance of breast cancer cells, but also that the metabolic byproduct, lactic acid, participates in the M2-like TAM polarization in the TME, activating the HIF-1α/STAT pathway.